460 results about "Ischemic disease" patented technology

Devices, systems and methods are provided for performing intra-lumenal medical procedures in a desired area of the body. Thrombectomy systems and methods of performing medical procedures to re-establish the intravascular flow of blood are provided for the treatment of ischemic disease states.

An intracellular calcium concentration increase inhibitor containing as the active ingredient (1) a boron compound represented by the formula (I).

The compound represented by the formula (I) inhibits the increase of the intracellular calcium concentration, and therefore it is deemed to be useful as an agent for the prophylaxis and/or treatment of platelet aggregation, ischemic diseases in hearts and brains, immune deficiency diseases, allorgosis, bronchial asthma, hypertension, cerebrovascular spasm, various renal diseases, pancreatitis, Alzheimer's disease, etc.

The present invention provides for a method for treating an ischemic disorder in a subject which comprises administering to the subject a pharmaceutically acceptable form of a selectin antagonist in a sufficient amount over a sufficient time period to prevent white blood cell accumulation so as to treat the ischemic disorder in the subject. The invention further provides a method for treating an ischemic disorder in a subject which comprises administering to the subject carbon monoxide gas in a sufficient amount over a sufficient period of time thereby treating the ischemic disorder in the subject. The invention further provides a method for treating an ischemic disorder in a subject which comprises administering to the subject a pharmaceutically acceptable form of inactivated Factor IX in a sufficient amount over a sufficient period of time to inhibit coagulation so as to treat the ischemic disorder in the subject.

The invention relates to compounds, compositions, drug delivery systems, and methods for treating age-related macular degeneration (AMD) and ocular ischemic disease in an individual in need.

The invention provides novel methods for treating disease based upon the medicinal use of lipids and phospholipids covalently bound to physiologically acceptable monomers or polymers. Phosphatidylethanolamine moieties conjugated to physiologically acceptable monomers and polymers (PE conjugates) manifest an unexpectedly wide range of pharmacological effects, including stabilizing cell membranes; limiting oxidative damage to cell and blood components; limiting cell proliferation, cell extravasation and (tumor) cell migratory behavior; suppressing immune responses; and attenuating physiological reactions to stress, as expressed in elevated chemokine levels. The surprisingly manifold pharmacological properties of the PL-conjugates allow for the invention, disclosed herein, of novel methods for the treatment of a diverse range of disease states, including obstructive respiratory disease, including asthma; colitis and Crohn's disease; central nervous system insult, including blood brain barrier compromise, ischemic stroke, and multiple sclerosis; contact dermatitis; psoriasis; cardiovascular disease, including ischemic conditions and prophylaxis for invasive vascular procedures; cellular proliferative disorders, including anti-tumor vasculogenesis, invasiveness, and metastases; anti-oxidant therapy; hemolytic syndromes; sepsis; acute respiratory distress syndrome; tissue transplant rejection syndromes; autoimmune disease; viral infection; and hypersensitivity conjunctivitis. The therapeutic methods of the invention include administration of phosphatidylethanolamine bound to carboxymethylcellulose, heparin, hyaluronic acid, polyethylene glycol, and Polygeline (haemaccel). Disclosed herein are also new compounds comprised of phospholipid moieties bound to low molecular weight monomers and dimers, including mono- and disaccharides, carboxylated disaccharides, mono- and dicarboxylic acids, salicylates, bile acids, and fatty acids.

The present invention provides a pharmaceutical composition and a method for reducing an infarct region resulting from the ischemic necrosis of cells, especially, a pharmaceutical composition and a method for suppressing ischemia-reperfusion injury in the treatment of ischemic heart disease. The pharmaceutical composition and the method utilize a substance, as an active ingredient, which can increase intracellular cGMP production by acting on a natriuretic peptide receptor, and which has the effect of reducing an infarct region. The substance is preferably a natriuretic peptide. The present invention is particularly useful for the treatment or prophylaxis of ischemic disease.

The present invention is based upon the observation that a mutant atrial natriuretic factor (ANF) gene increases stroke latency in spontaneously hypertensive rats-stroke prone (SHRSP). Accordingly, the present invention provides methods using mutant ANF proteins, fragments, analogs, derivatives and homologs of mutant ANF proteins, the nucleic acids encoding these mutant ANF proteins, as well as modulators of ANF for treating or preventing ischemic diseases, in particular ischemic stroke. The invention also relates to methods of diagnosis, prognosis and screening for a disposition for diseases and disorders associated with increased levels of ANF. Pharmaceutical compositions, methods of screening for ANF mutants and ANF modulators with utility for treatment and prevention of ischemic stroke are also provided.

Devices, systems and methods are provided for performing intra-lumenal medical procedures in a desired area of the body. Medical devices including filter devices, embolization devices, stents, delivery systems and methods of performing medical procedures to occlude, filter, redirect and or re-establish the intravascular flow of blood are provided for the treatment of hemorrhagic and ischemic disease states.

The invention relates to phthalazinone derivatives and application of the phthalazinone derivatives in the aspect of inhibiting the activity of poly(ADP-ribose)polymerase and the activity of histone deacetylases. The phthalazinone derivatives have the structure of formula (I). The median inhibitory concentration of partial compounds as shown in the formula (I) on the activity of poly(ADP-ribose)polymerase and the activity of histone deacetylases is about 10-7oml.L<-1>. The series of compounds can be used for preventing and treating tumors, local ischemic diseases, diabetes and inflammatory diseases.

The invention discloses a brain ASL, SPECT and MRI image registration and fusion conjoint analysis method and system. Registration is respectively carried out to an ASL image and an MRI image by taking the MRI image as a standard; the ASL image and an SPECT image are fused according to different transparencies; a region to be computed is marked in the faultage of the SPECT image; a closed curve is obtained through carrying out a cubic spline interpolation to the ASL image; the volume and the gray value corresponding to the region to be computed and the gray value of an interesting region body through a circular truncated cone approach mode. According to the invention, the advantages of the ASL image reflected brain blood perfusion, the SPECT image reflected brain blood perfusion and the MRI provided brain structure change are combined; an interesting region is segmented and analyzed through providing interactive calibration operation a doctor and a medical expert; the judgement accuracy of a brain ischemic disease is improved; and iconography instructions are provided for a clinician to formulate a rational therapeutic schedule.

Devices, systems and methods are provided for performing intra-lumenal medical procedures in a desired area of the body. Stents, stent delivery devices and methods of performing medical procedures to redirect and or re-establish the intravascular flow of blood are provided for the treatment of hemorrhagic and ischemic disease states.

The invention relates to a kind of decellularized blood vessel matrix gel, a preparation method therefor and applications thereof. The preparation method is as follows: first, after blood vessel outer membranes and anadesma are removed, the blood vessels are cut into blood vessel pieces, the blood vessel pieces are subjected to decellularized treatment in a TritonX-100 solution, then subjected to freeze drying, smashed into powder, and filtered with a 60-mesh screen, and decellularized blood vessel matrix powder is obtained; second, the decellularized blood vessel matrix powder is placed in a hydrochloric acid solution containing pepsin with a concentration of 0.09-0.11%, and subjected to digestion for 66-78h, a sodium hydroxide solution is added to neutralize hydrochloric acid, then PBS is added to balance ion concentration, finally, the gel solution is placed in an incubator with a temperature of 37 DEG C for gel forming. The decellularized blood vessel matrix gel has good molding capability and mechanical properties, the interior is loose, the gel has certain poriness, and the collagen fiber has appropriate diameters and good stability. The gel can meet requirements of preparation of medicines treating ischemic diseases, support materials of tissue engineering and/or cell culture.

The invention relates to medical application of protopanaxa-triol (PPT), protopanaxadiol (PPD) and mixtures of the PPT and the PPD in any proportion in nervous system diseases, which are preferably used for treating and/or preventing epilepsy, cerebral ischemic diseases, memory disorder and parkinsonism syndrome.

The present invention discloses one kind of stem cell preparation for treating tissue ischemia disease and its preparation process. The stem cell preparation includes mononuclear cell separated and extracted form peripheral blood, CD 133+ cell separated and extracted from other body's tissue, or vascular endothelial ancestral cell derived from CD133+cell. The preparation process includes separation and purification of stem cell, culture, preparation of cell suspension and other steps. The positive effect of the present invention is that the stem cell preparation has high curative effect and no toxic side effect to obliterative cardiac, cerebral and peripheral vascular and corresponding genetic defective diseases.

Devices, systems and methods are provided for performing intra-lumenal medical procedures in a desired area of the body. Stents, stent delivery devices and methods of performing medical procedures to redirect and or re-establish the intravascular flow of blood are provided for the treatment of hemorrhagic and ischemic disease states.

The present invention relates to Indenoisoquinolinone Analogs, compositions comprising an effective amount of an Indenoisoquinolinone Analog and methods for treating or preventing an inflammatory disease, a reperfusion injury, diabetes mellitus, a diabetic complication, reoxygenation injury resulting from organ transplantation, an ischemic condition, a neurodegenerative disease, renal failure, a vascular disease, a cardiovascular disease, cancer, a complication of prematurity, cardiomyopathy, retinopathy, nephropathy, neuropathy, erectile dysfunction or urinary incontinence, comprising administering to a subject in need thereof an effective amount of an Indenoisoquinolinone Analog.

The present invention relates to novel, non-peptidic small organic compounds having an affinity for cyclophilin (CyP)-type immunophilin proteins. In the compounds of this invention, at least two carbo- or heterocyclic groups are attached to a central saturated, partially saturated, or aromatic 5-6 membered carbocyclic ring by a combination of straight or branched linker chains. The invention further relates to pharmaceutical compositions comprising one or more of the said compounds, and to the uses of these compounds and compositions for binding CyP-type proteins, inhibiting their peptidyl-prolyl isomerase activity, and for research, development, and therapeutic applications in a variety of medical disorders, such as neurological disorders, hair loss disorders, ischemic disorders, and disorders caused by viral or protozoan infection.

A method for the diagnosis of acute myocardial, ischaemic diseases, for example acute myocardial infarct, particularly without increasing ST-paths in EKG (NSTEMI). At least two markers on a patient, who is to examined, are determined. A kit for carrying out said diagnostic method, including a test strip for carrying out quick tests.

The present invention relates to a function inhibitor of an effector cell comprising a CCR5 antagonist. Since the function inhibitor of an effector cell comprising a CCR5 antagonist inhibits the function of effector cells which play an important role in formation of diseases and the like, it is effective for the prevention and/or treatment of, for example, a transplant rejection (e.g., rejection of a solid organ graft, rejection of islet cell transplantation in diabetes mellitus, graft-versus-host disease (GVHD), etc.), an autoimmune disease (e.g., arthritis, rheumatoid arthritis, multiple sclerosis, ulcerative colitis, etc.), an allergic disease (e.g., asthma, etc.), an ischemic disease (e.g., ischemia-reperfusion injury, etc.), cancer or a metastatic disease or the like.